Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NCT00790699 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

31

Enrollment

OTHER

Sponsor class

Stopped Lack of patient population

Conditions

Type 1 Diabetes
Type 2 Diabetes

Interventions

DEVICE: I-PORT
OTHER: standard injections

Sponsor

Texas Diabetes & Endocrinology, P.A.

Collaborators

[object Object]